SEPN
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Septerna initiated a Phase 1 trial of SEP-479 for hypoparathyroidismApr 13, 2026
- Septerna reported positive Phase 1 results for SEP-631 and outlined an initial Phase 2 development planMar 2, 2026
- Septerna planned to present Phase 1 clinical data for SEP-631 in mast cell-driven diseases at the 2026 AAAAI annual meetingFeb 10, 2026
- Septerna announces dosing of first participants in Phase 1 clinical trial of SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator for mast cell-driven diseasesAug 21, 2025